Document is current

Article History

Received: 13 August 2024

Accepted: 10 October 2024

First Online: 9 November 2024

Declarations

:

: Saakshi Khattri is a speaker for AbbVie, Janssen, Lilly, and UCB; serves as an advisory board member/consultant for AbbVie, Janssen, Lilly, Novartis, and UCB; and has received research grants from AbbVie, BMS, LEO, Novartis, and Pfizer; Álvaro González-Cantero has served as a consultant for and received speaker fees from AbbVie, Janssen, Novartis, Almirall, Celgene, UCB, L'Oreal, MSD and Leo Pharma; Burhan Engin and Sunil Dogra has no conflict of interest to declare; Caroline A. Murphy, Christopher Schuster, Naoto Tsujimoto, Georgia Martimianaki, Anastasia Lampropoulou, Aya Alsharafi and Bruce Konicek are employees and shareholders of Eli Lilly and Company; Felix Lauffer has received speaker or consultant fees from Abbvie, Novartis Pharma, LEO Pharma, Lilly, Roche, Sanofi, Almirall, Janssen-Cilag Pharma Amgen, UCB Pharma, Boehringer-Ingelheim, Bristol-Myers-Squibb, and Union Therapeutics.

: The protocol, amendments, and consent documentation were approved by local institutional review boards (IRBs). The study was registered at the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCEPP24207) and was conducted according to International Conference on Harmonization, Good Clinical Practice guidelines, and the Declaration of Helsinki. All patients were required to give informed consent for participation in the study. We confirm that the necessary central or local IRB and/or ethics committee approvals have been obtained for this multi-site, international study by United BioSource LLC (UBC). Approvals can be provided on request.